OS Therapies Incorporated

AMEX:OSTX

Biotechnology

Healthcare
$1.15 +5.81%

+$0.10 today

Market cap
$53.83M
Beta
-0.95
P/E (TTM)
-2.0
EPS (TTM)
-$0.91
52W Low $1.15High $2.57

Volume 0.50M

Average 0.71M

OSTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

OS Therapies IncorporatedAMEX: OSTX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $10.4M (cash outflow) rose 168.2% year over year, behind the +254398.4% change in trailing-twelve-month net income. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +1562.8% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$20.38M (-99.9%) for the fiscal year ending Dec 2026, a slowdown from the +323597.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.4M-100.0% QoQ
Last fiscal yearDec 2025
-$28.75B+323597.5% YoY
LTMMar 2026
-$28.76B+254398.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+168.2%+32.1%-136.0 pp
1 year+323597.5%-99.9%-323697.4 pp
3-year CAGR+1562.8%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(28.75B) USD
Year-over-year change
-323597.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How OSTX compares with its peers on the latest reported figures

  • OSTX's LTM Mar 2026 net income of $28.76B is the largest of the 9 companies compared; the peer median is $33.23M.
  • Its year-over-year change of +254398.4% is the highest of 8, against a peer median of +1.8%.
  • Over three fiscal years its annual growth of +1562.8% compares with a peer median of -17.0%.
OSTX Competitors Peer median
Net Income for OSTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$28.76B +254398.4%+1562.8%—
INKTMiNK Therapeutics, Inc.LTM Mar 2026$12.49B +128201.2%-23.6%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$60.96M -388.6%-1.9%18297.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$37.19M -32.9%-5.5%—
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$34.61M -52.7%+4.2%164.8%
ADAGAdagene Inc.LTM Jun 2024$31.85M —-39.6%3904.3%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$24.54M +1.8%-10.4%1070.2%
EQEquillium, Inc.LTM Mar 2026$19.06M +36.2%-28.9%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$12.72M +12.6%-31.8%899.5%
Peer median (excluding OSTX) $33.23M+1.8%-17.0%1070.2%

Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.42M)(6.25M)(7.79M)(8.88M)(28.75B)
Depreciation & Amortization8058054.22K2.78K363.09M
Deferred Income Tax00000
Stock-Based Compensation000268.3K4.27B
Change in Working Capital574.67K947.33K2.02M(129.64K)9.11M
Accounts Receivables00000
Inventory00000
Accounts Payables856.48K216.43K1.35M(1.05M)8.27M
Other Working Capital(281.81K)730.9K669.65K923.69K834.81K
Other Non-Cash Items2.44M1.51M2.76M1.46M9.88B
Operating Cash Flow(4.4M)(3.79M)(3.01M)(7.28M)(14.24B)
Capital Expenditures(11.93K)000(466.42K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities212.41K230.88K1.15K0(465.96M)
Investing Cash Flow200.47K230.88K1.15K0(466.42M)
Debt Repayment2.95M3.82M3.16M1.5M0
Common Stock Issued0005.23M8.39M
Common Stock Repurchased00000
Dividends Paid000(31.25M)0
Other Financing Activities100K(172.02K)(284.18K)31.25M9.43B
Financing Cash Flow3.05M3.65M2.87M12.78M9.44B
Effect of Forex Changes00000
Net Change in Cash(1.15M)90.69K(132.5K)5.49M(5.26B)
Free Cash Flow(4.41M)(3.79M)(3.01M)(7.28M)(14.24B)

OS Therapies Incorporated

AMEX:OSTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.